Carmofur

• CAT Number: A000255
• CAS Number: 61422-45-5
• Molecular Formula: C11H16FN3O3
• Molecular Weight: 257.30
• Purity: ≥95%
• Synonyms: 61422-45-5; Mifurol; HCFU; Yamaful; 1-(n-hexylcarbamoyl)-5-fluorouracil
• Target: Anti-infection
• Solubility: >12.2mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 5-fluoro-N-hexyl-2,4-dioxopyrimidine-1-carboxamide
• InChI: InChI=1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)
• InChIKey: AOCCBINRVIKJHY-UHFFFAOYSA-N
• SMILES: CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F

Carmofur（Cat No.:A000255）is a chemotherapeutic agent derived from the 5-fluorouracil (5-FU) family, used primarily in the treatment of colorectal cancer. It functions by inhibiting thymidylate synthase, an enzyme crucial for DNA synthesis, thereby interfering with cancer cell replication. In addition, Carmofur is known to modulate fatty acid amide hydrolase (FAAH), potentially contributing to its anticancer effects. Unlike 5-FU, Carmofur is orally bioavailable and offers more convenient dosing. Its dual mechanisms make it a valuable option in cancer therapy, particularly for patients requiring sustained antitumor activity.

Reference

1: Domracheva I, Muhamadejev R, Petrova M, Liepinsh E, Gulbe A, Shestakova I,
Duburs G, Arsenyan P. 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC)
increases Carmofur stability and in vitro antiproliferative effect. Toxicol Rep.
2015 Jan 27;2:377-383. doi: 10.1016/j.toxrep.2015.01.009. eCollection 2015.
PubMed PMID: 28962371; PubMed Central PMCID: PMC5598257.

2: Miyazaki N, Tabata Y. Anti-tumor activity of carmofur water-solubilized by
lactic acid oligomer-grafted pullulan nanogels. J Nanosci Nanotechnol. 2009
Aug;9(8):4797-804. PubMed PMID: 19928152.

3: Sakamoto J, Hamada C, Rahman M, Kodaira S, Ito K, Nakazato H, Ohashi Y,
Yasutomi M. An individual patient data meta-analysis of adjuvant therapy with
carmofur in patients with curatively resected colon cancer. Jpn J Clin Oncol.
2005 Sep;35(9):536-44. Epub 2005 Sep 9. PubMed PMID: 16155120.

4: Morimoto K, Koh M. Postoperative adjuvant use of carmofur for early breast
cancer. Osaka City Med J. 2003 Dec;49(2):77-83. PubMed PMID: 15179836.

5: Kotake K, Koyama Y, Shida S, Tajima Y, Ishikawa H, Kanazawa K, Miyata M,
Nagamachi Y, Iwasaki Y, Omoto R, Tamakuma S, Kitajima M, Kodaira S; Neo-adjuvant
Chemotherapy for Colorectal Cancer Study Group. [Neo-adjuvant chemotherapy with
carmofur for colorectal cancer–a multi-institutional randomized controlled
study]. Gan To Kagaku Ryoho. 2002 Nov;29(11):1917-24. Japanese. PubMed PMID:
12465390.

6: Fujikawa A, Tsuchiya K, Katase S, Kurosaki Y, Hachiya J. Diffusion-weighted MR
imaging of Carmofur-induced leukoencephalopathy. Eur Radiol. 2001;11(12):2602-6.
Epub 2001 Jun 22. PubMed PMID: 11734966.

7: Ooi A, Ohkubo T, Higashigawa M, Kawasaki H, Kakito H, Kagawa Y, Kojima M,
Sakurai M. Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing
L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed
compound of tegafur and uracil), carmofur and 5/’-deoxy-5-fluorouridine. Biol
Pharm Bull. 2001 Nov;24(11):1329-31. PubMed PMID: 11725974.

8: Osako Y. [A case of reversible carmofur-induced leukoencephalopathy]. No To
Shinkei. 2001 Oct;53(10):986-7. Japanese. PubMed PMID: 11725511.

9: Osterlund P, Elomaa I, Virkkunen P, Joensuu H. A phase I study of raltitrexed
(Tomudex) combined with carmofur in metastatic colorectal cancer. Oncology.
2001;61(2):113-9. PubMed PMID: 11528249.

10: Nakamura T, Ohno M, Tabuchi Y, Kamigaki T, Fujii H, Yamagishi H, Kuroda Y;
Kansai Carmofur Study Group. Optimal duration of oral adjuvant chemotherapy with
Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial
III. Int J Oncol. 2001 Aug;19(2):291-8. PubMed PMID: 11445841.